1. [Analysis on prognosis and correlative factors of acute nonlymphocytic leukemia].
- Author
-
Liu CY, Fu R, Liu WH, Cheng YQ, Song WX, DU LJ, Ruan EB, Zhang LT, Wang XM, Liang Y, Wang GJ, Qu W, Song J, Zhang RL, Guan J, Li LJ, Song Y, Gao S, Liu H, Jiang HJ, Wang J, Zou P, and Shao ZH
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cytarabine administration & dosage, Cytarabine therapeutic use, Female, Harringtonines administration & dosage, Harringtonines therapeutic use, Humans, Leukemia, Myeloid, Acute diagnosis, Male, Middle Aged, Prognosis, Tretinoin administration & dosage, Tretinoin therapeutic use, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Myeloid, Acute drug therapy
- Abstract
To analyze the prognosis and risk factors of acute nonlymphocytic leukemia (ANLL), 94 patients with acute nonlymphocytic leukemia were enrolled in this study, while survival rate and risk factors of prognosis were analyzed. The results indicated that the complete remission (CR) ratio was 51.1%. Overall survival and event-free survival rates of month 6, 12, 18, 24 were 68.6%, 55.8%, 53.8%, 46.4%, 21.3% and 57.9%, 38.6%, 33.3%, 31.6%, 0% respectively. The factors such as age<40 years, WBC<10.0x10(9)/L before chemotherapy, WBC in the period of bone marrow suppression<1.0x10(9)/L, chemotherapy within 1 month after occurrence of leukemia, blood transfusion before chemotherapy of APL had favourable influence on remission and survival rates of ANLL patients. CR1, the time to get CR, length of CR and relapse significantly correlated with prognosis (p<0.05). It is concluded that the individualized therapy concerning the risk factors should be applied to ANLL patients for improving the remission, survival rate and prognosis.
- Published
- 2007